CompanyProfile_德赢vwin官网ac德赢vwin【官方合作伙伴】 CompanyProfile_德赢vwin官网ac德赢vwin【官方合作伙伴】



We are a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. We are dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. Our vision is to become a global leader in developing, manufacturing and commercializing innovative, next-generation and affordable therapeutic antibodies for patients worldwide.

Our business is designed to drive success through both efficient and breakthrough R&D innovation. We believe that fully integrated in-house R&D capabilities are critical to achieving success in China. Since our inception, we have had the foresight to develop an end-to-end platform, Akeso Comprehensive Exploration platform (“ACE Platform”), encompassing comprehensive drug discovery and development functionalities, including target validation, antibody drug discovery and development, CMC, and GMP-compliant manufacturing.

Through our ACE Platform, we have consistently and rapidly innovated and produced high quality drug candidates, with minimal dependence on external vendors, and have achieved remarkable results and industry recognition within seven years since our establishment.

Calendar of Events
  • January 2019

    The Company was incorporated in the Cayman Islands as an exempted company with l

  • March 2019

    We obtained the IND approval for 德赢 from the FDA to begin a Phase Ib/II clini

  • June 2019

    We formed Sino Biopharm Collaboration to co-develop and co-commercialize penpuli

  • June 2019

    We obtained the IND approval for a clinical trial ofAK112 in the United States

  • January 2018

    We initiated a Phase I clinical trial for AK101 in China

  • March and April 2018

    We obtained the IND approval for penpulimab (官网) with respect to cervical can

  • May 2018

    We initiated a Phase I clinical trial of ebronucimab (AK102) in China

  • October 2017

    We initiated a Phase I clinical trial (with chemotherapy) for 德赢 for the trea

  • December 2017

    We initiated a Phase I clinical trial for penpulimab (官网) in Australia

  • November 2015

    We out-licensed AK107 to Merck (code name in Merck is MK1308)

  • March 2012

    Akeso Biopharma ,our principal operating entity, was established in Zhongshan, C

  • April 2012

    We initiated the development of innovative ACE Platform and “TETRABODY” technolo